United Therapeutics CEO Executes 10b5-1 Option Exercise and Sale

United Therapeutics Corp ($UTHR) Form 4 Summary

Reporting Owner: Martine A. Rothblatt
Role: Chairperson & CEO, Director
Transaction Date: August 28, 2026
Filing Date: August 31, 2026

Key Details of Transactions

• Derivative Exercise: Exercised 9,500 stock options at an exercise price of $135.42 per share ($1,286,490 total exercise cost).
• Open Market Dispositions: Sold all 9,500 acquired shares across multiple tranches at prices ranging between $513.64 and $524.51, generating gross proceeds of approximately $4,916,363 (weighted average sale price of ~$517.51).
• Net Cash Realized: Approximately $3,629,873 (before taxes and transaction fees).

Nature of Ownership & 10b5-1 Plan

• The transactions were executed pursuant to a pre-arranged Rule 10b5-1 trading plan established on November 7, 2025.
• The shares and options are held indirectly by family trusts.
• Following the transactions, the reporting owner continues to hold 324,443 shares in this primary trust, 40,513 shares directly, and over 303,000 additional shares across various other family trusts.